Skip to main content
Clinical Trials/NCT01581320
NCT01581320
Completed
Phase 3

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R206 and Bonviva for the Improvement of Vitamin D in Postmenopausal Women With Osteoporosis

Alvogen Korea1 site in 1 country201 target enrollmentDecember 2011

Overview

Phase
Phase 3
Intervention
Test group
Conditions
Postmenopausal Women With Osteoporosis
Sponsor
Alvogen Korea
Enrollment
201
Locations
1
Primary Endpoint
A ratio of subject whose 25 OHD concentration is less than 15ng/mL
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of Dp-R206 and Bonviva for 16 weeks once a month on the improvement of vitamin D in postmenopausal women with osteoporosis.

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
September 2012
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Alvogen Korea
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Female more than 40 years old in postmenopausal

Exclusion Criteria

  • Subject who has a history of malignant cancer

Arms & Interventions

DP-R206

Intervention: Test group

Bonviva

Intervention: Reference group

Outcomes

Primary Outcomes

A ratio of subject whose 25 OHD concentration is less than 15ng/mL

Time Frame: 16weeks

A ratio of subject whose 25 OHD concentration is less than 15ng/mL after 16weeks

Secondary Outcomes

  • A ratio of subject whose 25 OHD concentration is less than 9ng/mL(16 weeks)
  • Safety evaluation (AE, Lab test, Vital sign etc)(16weeks)

Study Sites (1)

Loading locations...

Similar Trials